JPRN-jRCTs032220286已完成未知
Multicenter, Open-Label, Single-Arm, Exploratory Clinical Study Investigating the Efficacy and Safety of Tixel C Treatment in Patients with Meibomian Gland Dysfunction
Yuichi Hori0 个研究点目标入组 20 人开始时间: 2022年8月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
In this study, a constant efficacy and safety profile were suggested for thermomechanical ablation therapy (TMA) of the Tixel C device in patients presenting with meibomian gland dysfunction (MGD). In the future, it will be important to establish further effective protocols for MGD patients.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •It is intended for patients who meet all of the following criteria.
- •(1) Age 18 years and older of any gender or race.
- •(2) Provision of written informed consent prior to study participation.
- •(3) Patients who are participating in the study and can undergo all the treatments and tests prescribed in the protocol.
- •(4) Patients with dry eye symptoms in 3 months prior to obtaining consent and the Ocular Surface Disease Index (OSDI) questionnaire score of 23 or higher after obtaining consent.
- •(5) Patients with Tear Layer Breakdown Time (TBUT) of less than 10 seconds.
- •(6) Agreement/ability to abstain from dry eye/MGD medications for the time between the treatment visit/s and the final study visit. (Ocular lubricants are allowed if no changes are made during the study and already used prior to the study.)
- •(7) Fitzpatrick skin type I-VI
排除标准
- •Patients who is applicable those followings to be excluded.
- •(1) History of ocular surgery including intraocular, oculo-plastic, corneal or refractive surgery within 1 year.
- •(2) Patients with giant papillary conjunctivitis.
- •(3) Patients with punctal plugs or who have had punctal cautery.
- •(4) Ocular injury or trauma, chemical burns, or limbal stem cell deficiency within 3 months of obtaining consent.
- •(5) Active ocular herpes zoster or simplex of eye or eyelid or a history of these within the last 3 months of obtaining consent.
- •(6) Patients who are aphakic.
- •(7) Cicatricial lid margin disease identified via slit lamp examination, including pemphigoid, symblepharon, etc.
- •(8) Active ocular infection (e.g., viral, bacterial, mycobacterial, protozoan, or fungal infection of the cornea, conjunctiva, lacrimal gland, lacrimal sac, or eyelids including a hordeolum or stye).
- •(9) Active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months of obtaining consent (e.g., retinitis, macular inflammation, choroiditis, uveitis, iritis, scleritis, episcleritis, keratitis).
- •(10) Ocular surface abnormality that may compromise corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, or map dot fingerprint dystrophy).
- •(11) Lid surface abnormalities (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis) that may affect lid function in either eye.
- •(12) Anterior blepharitis (staphylococcal, demodex or seborrheic grade 3 or 4).
- •(13) Systemic disease conditions that cause dry eye (e.g., Stevens-Johnson syndrome, vitamin A deficiency, rheumatoid arthritis, Wegener granulomatosis, sarcoidosis, leukemia, Riley-Day syndrome, systemic lupus erythematosus, Sjogren syndrome).
- •(14) Unwillingness to abstain from systemic medications known to cause dryness for the study duration.
- •(15) Women in child baring age who are pregnant, nursing, or not utilizing adequate birth control measures.
- •(16) Individuals who have changed the dosing of either systemic or non-dry eye/MGD ophthalmic medication within the past 30 days prior to obtaining consent.
- •(17) Individuals who are unable or unwilling to remain on a stable dosing regimen for the duration of the study.
- •(18) Patients who have taken dry eye or MGD medications (antibiotics, nonsteroidal anti-inflammatory drugs, adrenal corticoster hormones) for at least two weeks or more within one year prior to obtaining consent. (Ocular lubricants are allowed if no changes are made during the study).
- •(19) Individuals wearing contact lenses at any time during the prior three months and at any point during the study.
- •(20) Current skin cancer, malignant sites and/or advanced premalignant lesions or moles in the treatment area.
- •(21) An impaired immune system condition or use of immunosuppressive medication.
- •(22) Keloid formation and/or abnormal wound healing.
- •(23) Patients who have received laser irradiation treatment at the treatment site for 3 months prior to the first treatment or require such treatment before the end of the study, or patients who have performed such treatment in the past.
- •(24) Any patient who takes or has taken any oral or topical medications, herbal treatment, food supplements, or vitamins which may cause fragile skin or impaired skin healing during the last 3 months of obtaining consent.
- •(25) Any patient who has a history of bleeding coagulopathies.
研究者
相似试验
已完成
不适用
Thermal Ablation in Larger Liver and Kidney TumoursLiver and Kidney TumoursNCT01720706University Health Network, Toronto12
Unknown
3 期
Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCCThermal AblationAnlotinibPDL-1Hepatocellular CarcinomaNCT04665609Chinese PLA General Hospital80
已完成
不适用
Evaluation for the Characterization of the Safety Profile of the DiamondTemp™ System for Fast Treatment of Patients With Atrial FibrillationAtrial FibrillationNCT03626649Medtronic Cardiac Rhythm and Heart Failure60
尚未招募
不适用
Pulsed Field Ablation in Three Different Substrate Ablation Strategies for Persistent Atrial FibrillationAtrial Fibrillation (AF)NCT06739512Shanghai Chest Hospital600
已完成
不适用
Evaluation of the Reproducibility of Ablation Volumes at One Month After Microwave Treatment Compared to the Manufacturer's Abacus: on the Kidney, Liver and LungHepatic TumorRenal TumorNCT04072224Centre Hospitalier Universitaire de Nīmes60